Women who are early risers and function at their best in the morning are less likely to develop breast cancer, a study has claimed.
Scientists who discovered the association also unearthed evidence of a causal link between sleeping longer and the disease.
The researchers compared data on hundreds of thousands of women found that those with an in-built morning preference were 40 % to 48 % less at risk of breast cancer.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
